Clinical trial · Interventional
Towards a Viral Etiology of Periodontal Disease in Relation to Radiotherapy Treatment of Head and Neck Cancers
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The treatment of otolaryngology (OLR) cancer is based on surgery, radiation, sometimes used in combination with chemotherapy. Patients treated with radiotherapy have multiple oral diseases: mucositis, hyposalivation, tissue fibrosis, exacerbation of periodontitis. Over 70% of patients with head and neck cancers treated with radiotherapy have a lower level of dental clinical attachment and 92% have loose teeth or missing. The management of these oral complications is a priority in OLR oncology. The aim is to improve the oral health of patients to achieve a comfortable life acceptable and necessary for healing. This project proposes to deepen the investigation with two main objectives: 1. To study in vivo the effect of radiation treatment on the evolution of the viral flora of the periodontium in a cohort of patients and matched controls. 2. To study in vitro the effects of irradiation on the replication EBV (herpesvirus) in producing websites lymphoepithelial tonsillar, and atypical dendritic cells associated with EBV that existence were recently discovered.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Periodontal Disease | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| periodontal pocket samples | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- periodontal disease
- description
- Saliva samples
- interventionNames
- Biological: periodontal pocket samples
Primary outcomes (2)
- measure
- Measure of level of EBV nucleic acids
- timeFrame
- day 1
- measure
- Measure of level of EBV nucleic acids
- timeFrame
- day 180
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Patients ≥ 18 years * Patients treated with curative radiotherapy on tumor site or surgery for cancer of the oral cavity and / or oropharynx * Patients naive treatments for head and neck cancers * Patients affiliated or beneficiary of a social security scheme * Patients who gave informed consent in writing Exclusion Criteria: * Patients treated with neoadjuvant chemotherapy, adjuvant or concomitant * Patients taking immunosuppressants after organ transplantation * Taking anticoagulants incompatible with dental samples (possible bleeding) * Patients edentulous and / or whose dental condition is incompatible with the dental samples
References
Publications (1)
- RESULTDe Monte A, Olivieri CV, Vitale S, Bailleux S, Castillo L, Giordanengo V, Maryanski JL, Segura E, Doglio A. CD1c-Related DCs that Express CD207/Langerin, but Are Distinguishable from Langerhans Cells, Are Consistently Present in Human Tonsils. Front Immunol. 2016 May 25;7:197. doi: 10.3389/fimmu.2016.00197. eCollection 2016. PMID 27252701